Seneca Biopharma (SNCA) Competitors

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Notice: This company has been marked as potentially delisted and may not be actively trading.

SNCA vs. CVM, CRIS, DTIL, GRTS, PLX, ATHA, ATRA, SGMO, ALVR, and TSBX

Should you be buying Seneca Biopharma stock or one of its competitors? The main competitors of Seneca Biopharma include CEL-SCI (CVM), Curis (CRIS), Precision BioSciences (DTIL), Gritstone bio (GRTS), Protalix BioTherapeutics (PLX), Athira Pharma (ATHA), Atara Biotherapeutics (ATRA), Sangamo Therapeutics (SGMO), AlloVir (ALVR), and Turnstone Biologics (TSBX). These companies are all part of the "medical" sector.

Seneca Biopharma vs.

Seneca Biopharma (NASDAQ:SNCA) and CEL-SCI (NYSE:CVM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their community ranking, valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

: In the previous week, CEL-SCI had 12 more articles in the media than Seneca Biopharma. MarketBeat recorded 12 mentions for CEL-SCI and 0 mentions for Seneca Biopharma. CEL-SCI's average media sentiment score of 0.55 beat Seneca Biopharma's score of 0.00 indicating that CEL-SCI is being referred to more favorably in the news media.
Company Overall Sentiment
Seneca Biopharma Neutral
CEL-SCI Positive
: 5.2% of Seneca Biopharma shares are held by institutional investors. Comparatively, 12.1% of CEL-SCI shares are held by institutional investors. 2.1% of Seneca Biopharma shares are held by insiders. Comparatively, 16.2% of CEL-SCI shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
: CEL-SCI has a net margin of 0.00% compared to Seneca Biopharma's net margin of -230.34%. Seneca Biopharma's return on equity of -122.20% beat CEL-SCI's return on equity.
Company Net Margins Return on Equity Return on Assets
Seneca Biopharma -230.34% -122.20% -110.61%
CEL-SCI N/A -204.28% -95.72%
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Seneca Biopharma
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
CEL-SCI
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
: Seneca Biopharma has higher revenue and earnings than CEL-SCI.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Seneca Biopharma $10K 11,415.36 -$8.35M N/A N/A
CEL-SCI N/A N/A -$32.19M -$0.68 -2.34
: Seneca Biopharma has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500. Comparatively, CEL-SCI has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500.
: Seneca Biopharma received 14 more outperform votes than CEL-SCI when rated by MarketBeat users. Likewise, 63.64% of users gave Seneca Biopharma an outperform vote while only 0.00% of users gave CEL-SCI an outperform vote.
Company Underperform Outperform
Seneca Biopharma Outperform Votes
14
63.64%
Underperform Votes
8
36.36%
CEL-SCI Outperform Votes
No Votes
Underperform Votes
8
100.00%

Company	Overall Sentiment
Seneca Biopharma	Neutral
CEL-SCI	Positive

Company	Net Margins	Return on Equity	Return on Assets
Seneca Biopharma	-230.34%	-122.20%	-110.61%
CEL-SCI	N/A	-204.28%	-95.72%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seneca Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
CEL-SCI	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seneca Biopharma	$10K	11,415.36	-$8.35M	N/A	N/A
CEL-SCI	N/A	N/A	-$32.19M	-$0.68	-2.34

Company	Underperform	Outperform
Seneca Biopharma	Outperform Votes 14 63.64%	Underperform Votes 8 36.36%
CEL-SCI	Outperform Votes No Votes	Underperform Votes 8 100.00%

Summary

Seneca Biopharma and CEL-SCI tied by winning 6 of the 12 factors compared between the two stocks.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

Get Seneca Biopharma News Delivered to You Automatically

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNCA vs. The Competition

Export to Excel

Metric	Seneca Biopharma	Biological Products, Except Diagnostic Industry	Medical Sector	NASDAQ Exchange
Market Cap	$114.15M	$2.53B	$4.77B	$7.45B
Dividend Yield	N/A	2.29%	2.98%	3.99%
P/E Ratio	N/A	19.21	187.06	14.57
Price / Sales	11,415.36	300.57	2,532.50	88.16
Price / Cash	N/A	138.39	46.78	35.01
Price / Book	4.96	3.78	4.63	4.22
Net Income	-$8.35M	-$45.84M	$102.78M	$211.98M

Seneca Biopharma Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CVM CEL-SCI	0 of 5 stars	$1.71 -3.9%	N/A	N/A	$92.31M	N/A	-2.51	N/A	Analyst Revision News Coverage
CRIS Curis	1.4853 of 5 stars	$15.58 -5.6%	$37.33 +139.6%	-19.4%	$91.83M	$10.02M	-1.74	49	Gap Up
DTIL Precision BioSciences	3.7504 of 5 stars	$13.84 +2.3%	$60.00 +333.5%	-53.5%	$95.77M	$48.73M	-0.86	115	Analyst Report
GRTS Gritstone bio	1.8299 of 5 stars	$0.98 -3.0%	$6.33 +547.1%	-73.9%	$95.98M	$16.34M	-0.82	231	Analyst Revision
PLX Protalix BioTherapeutics	2.5997 of 5 stars	$1.32 +1.5%	$10.00 +657.6%	N/A	$96.43M	$65.49M	26.41	208
ATHA Athira Pharma	2.0425 of 5 stars	$2.52 +4.1%	$12.00 +376.2%	-23.3%	$96.59M	N/A	-0.82	65
ATRA Atara Biotherapeutics	3.8232 of 5 stars	$0.75 -1.3%	$28.00 +3,636.8%	-76.4%	$89.44M	$8.57M	-0.29	334
SGMO Sangamo Therapeutics	0.5347 of 5 stars	$0.56 flat	$4.93 +775.7%	-70.1%	$100.62M	$176.23M	-0.38	405	Positive News
ALVR AlloVir	1.5893 of 5 stars	$0.74 +1.4%	$18.67 +2,409.3%	-81.4%	$85.47M	N/A	-0.40	112
TSBX Turnstone Biologics	2.2003 of 5 stars	$3.52 +14.3%	$19.00 +439.8%	N/A	$81.31M	$19.31M	0.00	94	News Coverage

Related Companies and Tools

Related Companies:

Top 10 Stock Comparisons

This page (NASDAQ:SNCA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Seneca Biopharma (SNCA) Competitors

SNCA vs. CVM, CRIS, DTIL, GRTS, PLX, ATHA, ATRA, SGMO, ALVR, and TSBX

Seneca Biopharma vs.

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNCA vs. The Competition

Seneca Biopharma Competitors List

Related Companies and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info